LFSCvsSBIOETF Comparison
VS
F/m Emerald Life Sciences Innovation ETF (LFSC) belongs to the Life Sciences segment. ALPS Medical Breakthroughs ETF (SBIO) is part of the Tomorrow's Treatments segment. LFSC's top 3 sector exposures are Healthcare and Sovereign. In contrast, SBIO's top sector exposures are Healthcare and Non-Corporate. LFSC is more expensive with a Total Expense Ratio (TER) of 0.79%, versus 0.5% for SBIO. LFSC is up 23.23% year-to-date (YTD) with +$8M in YTD flows. SBIO performs better with 24.58% YTD performance, and +$41M in YTD flows. Run a side-by-side ETF comparison of LFSC and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
LFSC vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/24/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | LFSC SBIO | +4.17%+4.86% | +20.39%+17.16% | +23.23%+24.58% | +82.30%+91.81% | n/a+109.04% | n/a+48.00% |
| Flows | LFSC SBIO | +$2M+$18M | +$3M+$24M | +$8M+$41M | +$17M+$51M | -+$20M | --$24M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | LFSC SBIO | +26.23%+35.36% | +26.91%+30.55% | n/a+30.92% | n/a+33.95% |
| Max drawdown | LFSC SBIO | -6.53%-10.73% | -16.25%-12.63% | n/a-42.12% | n/a-52.50% |
| Max drawdown duration | LFSC SBIO | 20d43d | 168d60d | n/a331d | n/a1479d |
Trading data
LFSC | SBIO | |
Last sale 7/24/2026 at 1:30 PM | $45.10 | $63.77 |
| Previous close 07/23/2026 | $45.46 | $64.33 |
| Consolidated volume 07/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
LFSC
is actively managed and doesn’t replicate an indexLFSC | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/24/2026 at 1:30 PM
Live
Closed
LFSC | SBIO | |
|---|---|---|
| Last price | $45.10 | $63.77 |
| 1D performance | -0.79% | -0.88% |
| AuM | $123.48 M | $202.25 M |
| E/R | 0.79% | 0.5% |
Characteristics
LFSC | SBIO | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Emerald Group | ALPS |
| Benchmark | - | S-Network Medical Breakthroughs Index |
| N° of holdings | 40 | 103 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | October 31, 2024 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
LFSC
USA
90.9%
United Kingdom
7.04%
Other
2.06%
SBIO
USA
88.02%
Other
11.98%
Sectors
LFSC
Healthcare
98.03%
Other
1.97%
SBIO
Healthcare
99.06%
Other
0.94%
Diversification
LFSC
Total weight of top 15 holdings out of 15
73.24%
SBIO
Total weight of top 15 holdings out of 15
40.08%
Top 15 holdings
Data as of June 30, 2026
LFSC
Travere Therapeutics, Inc.
8.37%
Cogent Biosciences, Inc.
7.18%
LivaNova Plc
7.04%
Spyre Therapeutics, Inc.
6.71%
Guardant Health, Inc.
5.56%
Corcept Therapeutics, Inc.
5.27%
Mirum Pharmaceuticals, Inc.
5.25%
BillionToOne, Inc.
4.25%
Cytokinetics, Inc.
4.13%
Veradermics, Inc.
3.76%
United Therapeutics Corp.
3.55%
Trevi Therapeutics, Inc.
3.50%
Savara, Inc.
3.20%
Dianthus Therapeutics, Inc.
2.77%
Nektar Therapeutics
2.70%
SBIO
Apogee Therapeutics, Inc.
4.36%
CG Oncology, Inc.
3.33%
Xenon Pharmaceuticals, Inc.
3.09%
Oruka Therapeutics, Inc.
3.05%
Dianthus Therapeutics, Inc.
2.83%
Travere Therapeutics, Inc.
2.80%
Definium Therapeutics, Inc.
2.73%
Veradermics, Inc.
2.72%
Edgewise Therapeutics, Inc.
2.32%
ACADIA Pharmaceuticals, Inc.
2.30%
Denali Therapeutics, Inc.
2.17%
Relay Therapeutics, Inc.
2.17%
NewAmsterdam Pharma Co. NV
2.10%
Crinetics Pharmaceuticals, Inc.
2.09%
Structure Therapeutics, Inc.
2.02%
Frequently asked questions about LFSC and SBIO
How have the LFSC and SBIO ETFs performed in 2026?
As of July 24, 2026, LFSC is up 23.23% year-to-date (YTD), while SBIO has returned 24.58%. That puts SBIO better performer ahead so far this year.
Which ETF is attracting more investor money: LFSC or SBIO?
Year-to-date, the LFSC ETF saw +$8M in flows, compared to +$41M for SBIO.
Which ETF is more volatile: LFSC or SBIO?
Over the past year, LFSC had a volatility of 26.91%, while SBIO experienced 30.55%.
Which ETF is bigger: LFSC or SBIO?
As of July 24, 2026, LFSC holds $123.48 M in assets under management (AUM), while SBIO manages $202.25 M.
What sectors do the LFSC and SBIO ETFs invest in?
LFSC leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the LFSC ETF and SBIO ETF?
LFSC top holdings include Travere Therapeutics, Inc., Cogent Biosciences, Inc. and LivaNova Plc. SBIO holds in its top three: Apogee Therapeutics, Inc., CG Oncology, Inc. and Xenon Pharmaceuticals, Inc..
Which ETF is more diversified: LFSC or SBIO?
LFSC holds 40 securities with 73.24% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 40.08%.
Advertisement
Latest news about LFSC & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
